Comparison of 2 NovoFine® Needles on the Reflux of Insulin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00872560
Recruitment Status : Completed
First Posted : March 31, 2009
Last Update Posted : February 28, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S

March 30, 2009
March 31, 2009
February 28, 2017
January 20, 1998
July 27, 1998   (Final data collection date for primary outcome measure)
Weighing of reflux of insulin [ Time Frame: 6 seconds after injection ]
Weighing of reflux of insulin [ Time Frame: at least 5 seconds after injection ]
Complete list of historical versions of study NCT00872560 on Archive Site
  • Pain perception [ Time Frame: after 6 weeks of treatment ]
  • Number and severity of bleedings [ Time Frame: after 6 weeks of treatment ]
  • Reactions at injection sites [ Time Frame: after 6 weeks of treatment ]
Same as current
Not Provided
Not Provided
Comparison of 2 NovoFine® Needles on the Reflux of Insulin
Insulin Leakage and Pain Perception in IDDM Children or Adolescents, Where the Injections Are Performed With NovoFine™ 6 x 0.30 mm Needles and NovoFine® 8 x 0.30 mm Needles: An Open, Randomized, Two-period Cross-over, Multi-centre, Phase IIIb Trial at 4 Centres
This trial is conducted in Europe. This trial aims to ensure that there is no substantial clinically relevant difference between the two Novo Nordisk needles NovoFine® 6 x 0.30 mm and NovoFine® 8 x 0.30 mm on reflux of insulin back to the surface of cutis.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Diabetes
  • Diabetes Mellitus, Type 1
  • Delivery Systems
  • Device: NovoFine® needle 6 mm
    Other Name: NEEDLEN
  • Device: NovoFine® needle 8 mm
    Other Name: NEEDLEN
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
July 27, 1998
July 27, 1998   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Children/adolescents with type 1 diabetes mellitus
  • Usage of NovoPen® 1.5 for at least 3 months
  • Duration of insulin treatment more than 1 year
  • Normal weight according to Tanner scales
  • The means of the last 2 HbA1c measurements taken within the last 6 months must be less than 10.5%

Exclusion Criteria:

  • Pregnancy or desire to become pregnant
  • Clinical relevant peripheral neuropathy as judged by the investigators
  • Pronounced lipodystrophy in accordance with investigator's evaluation
  • Use of drugs that can influence the trial
  • Coagulation disorders (use of anti-coagulants)
  • Serious, chronic diseases, making it highly unlikely that the subject can complete the trial
Sexes Eligible for Study: All
10 Years to 17 Years   (Child)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP